<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infections</z:e> with Coxsackieviruses have been linked to <z:hpo ids='HP_0006279'>beta cell dysfunction</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Given the importance of <z:hpo ids='HP_0006279'>beta cell dysfunction</z:hpo> in the aetiology of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, we hypothesised that prior <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> with Coxsackieviruses B would increase the risk of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>The aims of the study were to estimate cross-sectional associations between potential predictors of previous <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and seropositivity for Coxsackievirus B serotypes 1-5 (CBV1-5), and then to assess the association between seropositivity and incident type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Using a case-cohort design nested within the European Prospective Investigation of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> (EPIC)-Norfolk study, we ascertained n = 603 cases of incident type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>From within the entire cohort we identified a random subcohort of n = 835, without <z:mp ids='MP_0002055'>diabetes</z:mp> at baseline </plain></SENT>
<SENT sid="5" pm="."><plain>The presence of Coxsackievirus B neutralising antibodies against serotypes 1-5 was assessed using a plaque neutralisation assay </plain></SENT>
<SENT sid="6" pm="."><plain>Weighted Cox regression was used to examine the association between presence of antibodies to CBV1-5 and the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Seropositivity in the subcohort for CBV1-5 was 50%, 67%, 66%, 75% and 45%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>After adjustment for age, sex, BMI, physical activity and family history of <z:mp ids='MP_0002055'>diabetes</z:mp>, the presence of antibodies against CBV1-5 was not associated with incident type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, over a mean follow-up of 5.7 years (HR [95% CIs] 0.94 [0.72,1.25], 0.92 [0.68, 1.23], 1.33 [0.98,1.81], 1.16 [0.83,1.61] and 1.03 [0.77,1.39] for CBV1-5, respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/INTERPRETATION: The presence of antibodies against any of five serotypes of Coxsackievirus B was not associated with incident type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>